Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers

Yang Zheng; Jiayu Zou; Chen Sun; Fu Peng; Cheng Peng

doi:10.3389/fmolb.2023.1165781

Ado-tratuzumab emtansine beyond breast cancer: therapeutic role of targeting other HER2-positive cancers

Front Mol Biosci. 2023 May 11:10:1165781. doi: 10.3389/fmolb.2023.1165781. eCollection 2023.

Authors

Yang Zheng¹, Jiayu Zou¹, Chen Sun¹, Fu Peng^{2

3}, Cheng Peng¹

Affiliations

¹ State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
² Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
³ Sichuan University, Chengdu, Sichuan, China.

Abstract

Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved by the FDA in 2013 for advanced HER2-positive breast cancer treatment exhibiting promising clinical benefits. However, HER2 overexpression and gene amplification have also been reported in other cancers like gastric cancer, non-small cell lung cancer (NSCLC), and colorectal cancer. Numerous preclinical studies have also revealed the significant antitumor effect of T-DM1 on HER2-positive tumors. With the advancement in research, several clinical trials have been conducted to investigate the antitumor effect of T-DM1. In this review, we briefly introduced the pharmacological effects of T-DM1. We reviewed its preclinical and clinical studies, especially on other HER2-positive cancers, establishing what has been encountered between its preclinical and clinical studies. In clinical studies, we found that T-DM1 has a therapeutic value on other cancers. An insignificant effect was observed on gastric cancer and NSCLC, inconsistent with the preclinical studies.

Keywords: HER2+; T-DM1; cancer; targeted therapy; therapeutic potential.

Publication types

Review

Grants and funding

The study was supported by the National Natural Science Foundation of China (Nos. 82003879 and U19A2010), the Key Project of Science and Technology Department of Sichuan Province (No. 2021YFS0044), the National Natural Science Foundation of Science and Technology Department of Sichuan Province (No. 2023NSFSC 1928), the Project of State Administration of Traditional Chinese Medicine of China (No. ZYYCXTD-D-202209), Young Elite Scientist Sponsorship Program by China Association for Science and Technology (no. CACM-2020-QNRC1-01), the Traditional Chinese Medicine Science and Technology Industry Innovation Team of Sichuan Province, and the Multi-dimensional Evaluation and product Development Innovation Team of Characteristic Traditional Chinese Medicine Resources (No. 2022C001).